Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
XL820 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | - |
| B | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| XL820 | DRUG | XL820 capsules administered orally as a single agent at a dose of 800 mg daily |
Inclusion Criteria: * Patients with metastatic or locally advanced or unresectable GIST who have intolerance of or disease progression following prior treatment with imatinib and/or sunitinib * ECOG (Eastern Cooperative Oncology Group) performance status ≤2 * Must have measurable disease per RECIST...
XL820 is an investigational small molecule being studied for the treatment of cancer, including gastrointestinal stromal tumors (GIST). It was evaluated in clinical trials for adults with solid tumors and for advanced GIST resistant to imatinib and/or sunitinib. XL820 is not approved and remains in clinical development.
XL820 is being developed by Exelixis, Inc., a biopharmaceutical company traded on NASDAQ under the ticker EXEL. The company sponsored clinical trials of XL820 in the United States for the treatment of cancer and gastrointestinal stromal tumors.
XL820 has completed Phase 1 and Phase 2 clinical trials. Two Phase 1 studies in adults with solid tumors and one Phase 2 study in advanced GIST have been completed. XL820 is an investigational drug and is not FDA approved.
XL820 has been studied in three completed clinical trials: NCT00129571, a Phase 1 study in adults with solid tumors; NCT00350831, a Phase 1 study of oral XL820 in subjects with solid tumors; and NCT00570635, a Phase 2 study in adults with advanced GIST resistant to imatinib and/or sunitinib.
XL820 is a small molecule designed to target cancer cells. Its specific molecular target has not been disclosed in the available clinical trial information. The drug was administered orally in trials for solid tumors and gastrointestinal stromal tumors.